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SUMMARY
Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and 
transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions 
Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse 
events, all of which were grade 2. Among 23 children completing 30 months of study treatment, 
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the net iron balance was favourable (−8.7 mg Fe/kg) with significant decrease in ferritin, although 
liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well-
tolerated, with net iron removal in most children who completed 30 months of protocol-directed 
treatment.
Keywords
sickle cell; iron overload; phlebotomy; liver iron
INTRODUCTION
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH, ClinicalTrials.gov 
NCT00122980), a National Heart, Lung and Blood Institute-sponsored Phase III multicentre 
trial, compared chronic blood transfusions with chelation (Standard Arm) to 
hydroxycarbamide (alos known as hydroxyurea) with phlebotomy (Alternative Arm) for 
reduction of recurrent stroke and improvement in iron overload management in children 
with sickle cell anaemia (SCA) and stroke (Ware et al, 2011). SWiTCH was terminated due 
to statistical futility and stroke rate differences (Ware & Helms, 2012). We describe the 
SWiTCH phlebotomy experience including feasibility, success rates, adverse events and 
effects on net iron balance and liver iron stores.
METHODS
Children between 5.0 and 18.9 years of age with SCA and previous stroke were eligible for 
enrollment if they had received ≥18 months of transfusions and had iron overload (Ware et 
al, 2011). Subjects with baseline liver iron concentration (LIC) ≥5 mg Fe/g dry weight liver 
were eligible for randomization; those on the Alternative Arm commenced 
hydroxycarbamide at 20 mg/kg/day while continuing transfusions for a short overlap period, 
to provide protection against recurrent stroke during hydroxycarbamide dose escalation to 
maximum tolerated dose (MTD). Transfusion volumes provided during this overlap period 
were progressively decreased every 8 weeks, while the hydroxycarbamide dose was 
increased by 5 mg/kg/day increments every 8 weeks to the MTD (Zimmerman et al, 2004; 
Heeney & Ware, 2008). During this overlap period, the subjects did not receive chelation 
therapy. Once hydroxycarbamide MTD was reached, transfusions were discontinued and the 
subjects started serial phlebotomy. Quantitative LIC (Mayo Laboratories, Rochester MN) 
was measured by liver biopsy at study entry and exit, and serum ferritin was monitored 
monthly.
Therapeutic phlebotomy was performed every 4±1 weeks. The initial procedure was 
performed at 5 ml/kg. If well tolerated, subsequent phlebotomy volumes were increased to 
10 ml/kg, with a maximum volume of 500 ml removed at any procedure when Hb ≥80 g/l. 
For Hb concentration of 70-79 g/l, the phlebotomy volume was decreased to 5 ml/kg, and 
phlebotomy was not performed if Hb was <70 g/l or when protocol-defined haematological 
toxicities were present. Phlebotomy was performed over 30-45 min followed by replacement 
with an equal volume of normal saline.
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Iron loading was calculated using the actual volume of each transfusion as follows: [(volume 
of transfusion in l) × (220 g Hb/l) × (3.4 mg Fe/g Hb)] / (subject's weight in kg). For 
phlebotomies, iron unloading was based on the actual blood volume removed and the 
subject's Hb on the day of phlebotomy: [(volume of phlebotomy in l) × (subject's Hb 
concentration in g/l) × (3.4 mg Fe/g Hb)] / (subject's weight in kg).
Descriptive statistics (mean, standard deviation, median and range) were performed for 
demographic variables, transfusion history, chelation history and baseline laboratory values. 
T-tests were used to examine the relationship of baseline LIC and serum ferritin levels and 
change in iron load. Associations between continuous variables were evaluated using the 
Spearman correlation coefficient. P-values less than 0.05 were considered statistically 
significant, no multiple comparisons adjustments were made and all analyses were 
conducted using SAS Version 9.2 (SAS, Cary, NC) and STATA Version 13.0 (STATA, 
College Station, TX).
RESULTS
Sixty-seven subjects (mean age 13.0±4.0 years; range 5.2-19.0 years; 61% male) were 
randomized to the Alternative Treatment Arm (Ware & Helms, 2012). The average duration 
of previous transfusion therapy was 7.4±3.8 years (median 7.6 years, range 1.5-15.5 years). 
Most children had previously received chelation: 47 (71%) with deferoxamine for 4.8±3.2 
years and 57 (86%) with deferasirox for 1.5±0.8 years prior to study enrollment 
(Kwiatkowski et al, 2011).
Sixty of 67 subjects successfully escalated hydroxycarbamide to MTD and then initiated 
phlebotomy after receiving an average of 8±3 overlap transfusions. The remaining 7 did not 
transition to phlebotomy due either to hydroxycarbamide non-adherence (N=5), early study 
termination (N=1), or stroke recurrence during the overlap (N=1). A total of 23 subjects on 
the Alternative Treatment Arm (38% of the 60 receiving phlebotomy) completed the 
prescribed 30 months and received an exit liver biopsy; among the remaining 37, 26 were 
still on treatment when SWiTCH was closed, 6 had an adjudicated recurrent stroke and 4 
others withdrew. The last subject never discontinued transfusions due to poor 
hydroxycarbamide adherence; her data were excluded from iron loading/unloading analyses 
because she never received phlebotomy.
A total of 927 therapeutic phlebotomy procedures were performed on 60 subjects (mean 
15±8, median 16, range 1-28 procedures per subject). Of those, 909 (98%) were performed 
at protocol-directed volumes including 741 at 10 ml/kg or 500 ml, 108 at 5 ml/kg for Hb 
70-79 g/l, and 59 at 5 ml/kg per protocol for the first scheduled phlebotomy. Only 26 (3%) 
of phlebotomy procedures stopped before the scheduled volume was removed, typically 
from loss of venous access. Phlebotomy removed an average of 127±74 ml/kg blood, 
representing 8.5 ml/kg of blood removed per procedure. The 23 children who completed 30 
months of study treatment received an average of 23 phlebotomy procedures, removing 
193.3±46.7 ml/kg blood. There were 119 off-protocol transfusions administered during the 
phlebotomy phase, including 52 given to 5 children with medication non-compliance and 37 
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during the exit window, most commonly before general anaesthesia for end-of-study liver 
biopsy or brain magnetic resonance imaging/angiogram.
There were 33 adverse events (AEs, 3.5% prevalence) associated with phlebotomy reported 
in 12 subjects. All 33 AEs were Grade 2 and self-limited, with no serious adverse events 
(SAE). The most common AE was hypotension (9 events in 5 subjects) followed by 
dizziness (3), syncope (3), headache (2) and weakness (2).
In the entire cohort of children receiving phlebotomy, serum ferritin decreased significantly 
from 3272±1587 μg/l at study entry to 2772±1564 μg/l at phlebotomy initiation (p=0.007) 
and then further to 2097±1631 μg/l at study exit (p<.001 entry to exit, p<0.001 first 
phlebotomy to exit,Table I). In the 23 subjects who completed treatment, serum ferritin 
decreased significantly from 3462±1387 μg/l at entry to 2793±1595 μg/l when starting 
phlebotomy (p=0.01) and then further to 2036±1838 μg/l at exit (p<0.0001 entry to exit, 
p=0.001 first phlebotomy to exit, Table I). In this smaller cohort, average net iron balance 
was −8.7 mg Fe/kg (range −83.4 to +67.5 mg Fe/kg); the highly positive values reflect 2 
subjects who restarted chronic transfusions for non-adherence to hydroxycarbamide. 
However, their overall average LIC was unchanged, from an entry value of 18.0±9.1 mg 
Fe/g dry weight liver (median 15.9 range 6.4-42.4) to 18.2±10.8 mg Fe/g at exit (median: 
17.2, range: 2.5-38.2, p=0.86). These inconsistencies between iron balance and change in 
LIC raise concerns about the accuracy and validity of liver biopsy as a marker of total body 
iron burden. There was no association between net change in LIC and calculated net iron 
change (Figure 1A) or change in ferritin (Figure 1B). However, changes in the ferritin levels 
correlated with net iron balance (p=0.01; Figure 1C). Among univariate models examined 
with regression analyses (age, sex, duration of transfusions, ferritin and LIC), only baseline 
ferritin was significantly associated with change in LIC (p=0.04).
DISCUSSION
SWiTCH provides a large prospective data set concerning the feasibility, safety and benefits 
of serial phlebotomy for removing transfusional iron burden in children with SCA. Our 
experience suggests phlebotomy is both safe and feasible, even when performed in anaemic 
children with previous stroke. Almost all scheduled phlebotomy procedures occurred at the 
prescribed volume; the rate of AE was quite low with no SAE.
The effects of repeated phlebotomy on iron burden were reflected in significantly lower 
serum ferritin (Figure 1C). The most important question, and also the primary reason for 
premature termination of SWiTCH, is why serial phlebotomy did not significantly decrease 
LIC in children randomized to the Alternative Treatment Arm. The actual overlap period, 
plus occasional unscheduled transfusions, added 49 mg Fe/kg, substantially more iron 
loading than the predicted 35 mg/kg. Moreover, actual phlebotomy procedures removed 
only 60 mg Fe/kg among 23 children who completed the phlebotomy phase, substantially 
less than the 82 mg/kg iron unloading predicted by the protocol. Additional contributors to 
reduced iron unloading include age and weight of the SWiTCH subjects, which limited their 
phlebotomy volumes to 500 ml. Together, these help explain why net iron unloading in the 
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Alternative Arm was less than predicted, but do not explain why negative iron balance 
among subjects completing the study was not accompanied by LIC reduction.
Phlebotomy for transfusional iron overload can use an intensive schedule (Angelucci et al 
1997, Franchini et al, 2004), and with longer duration, can normalize iron stores in children 
with SCA and stroke (Ware et al, 1999; Ware et al, 2004), and then maintain low iron 
burden (Greenway et al, 2011). The lack of observed LIC change probably relates to the 
inherent inaccuracy of biopsy-guided LIC measurements, probably due to sampling errors, 
because no significant associations were observed between net iron balance and LIC change. 
The SWiTCH experience documents that therapeutic phlebotomy is well-tolerated in 
children with SCA, stroke and iron overload. Serial blood removal was feasible and safe, 
and the data suggest this approach can be effective treatment for selected patients with 
transfusional haemosiderosis who discontinue transfusions, particularly if phlebotomy is 
provided for an extended period of time.
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Figure 1. 
Correlations of net iron balance with change in liver iron concentration (LIC) (1A), change 
in ferritin and LIC (1B) and change in net iron balance with change in ferritin (1C).
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